secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-098474
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics reports Q4 2025 net loss of $16.0M; cash $219.8M funds operations into 2029
--------------------------------------------------------------------------------

- Full-year 2025 net loss $69.8M; R&D expenses $59.1M, G&A $20.3M.
- Cash, equivalents and securities $219.8M as of Dec 31, 2025; runway into 2029.
- DT-216P2 (FA) RESTORE-FA trial ongoing; frataxin data expected H2 2026.
- DT-168 (FECD) Phase 2 biomarker trial data anticipated H2 2026.
- DT-818 (DM1) Phase 1 MAD trial dosing expected H1 2026; results in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000119312526098474/0001193125-26-098474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000119312526098474/dsgn-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-098474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer